Single dose PK study on Patients [Design Issues]

posted by Pharma_88 – India, 2024-05-17 12:06 (768 d 09:09 ago) – Posting: # 23998
Views: 6,406

Dear Ohlbe,

Thank you for responding. Drug is Olaparib and OGD recommends Two-way crossover Steady State PK study. One of our client wish to conduct single dose BE study as a conventional design without interrupting ongoing treatment of patient. Now whether its a feasible by taking appropriate measures of clinical safety?

Regards,
Pharma_88


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
151 visitors (0 registered, 151 guests [including 33 identified bots]).
Forum time: 21:16 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5